Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection


-- Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease

See the original post:
Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Related Posts